Ardelyx, Inc. (NASDAQ: ARDX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.23 | Insider Own | 4.66% | Shs Outstand | 247.03M | Perf Week | -4.47% |
| Market Cap | 844.84M | Forward P/E | 13.17 | EPS next Y | 0.26 | Insider Trans | -4.00% | Shs Float | 237.16M | Perf Month | -15.14% |
| Enterprise Value | 1.00B | PEG | 6.18 | EPS next Q | -0.03 | Inst Own | - | Short Float | 9.58% | Perf Quarter | -43.47% |
| Income | -55.51M | P/S | 1.87 | EPS this Y | 20.36% | Inst Trans | - | Short Ratio | 5.35 | Perf Half Y | -37.82% |
| Sales | 450.90M | P/B | 5.69 | EPS next Y | 241.81% | ROA | -9.67% | Short Interest | 22.72M | Perf YTD | -41.34% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -36.00% | 52W High | 8.40 -59.29% | Perf Year | -44.75% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -7.96% | 52W Low | 3.33 2.70% | Perf 3Y | -25.49% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 98.55% 119.43% | Gross Margin | 93.96% | Volatility | 3.48% 3.49% | Perf 5Y | 151.47% |
| Dividend TTM | - | EV/Sales | 2.23 | EPS Y/Y TTM | -35.29% | Oper. Margin | -7.86% | ATR (14) | 0.15 | Perf 10Y | 20.85% |
| Dividend Ex-Date | - | Quick Ratio | 3.15 | Sales Y/Y TTM | 19.16% | Profit Margin | -12.35% | RSI (14) | 25.68 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.34 | EPS Q/Q | 12.50% | SMA20 | -7.04% | Beta | 0.64 | Target Price | 13.00 |
| Payout | 0.00% | Debt/Eq | 1.72 | Sales Q/Q | 23.47% | SMA50 | -20.43% | Rel Volume | 1.47 | Prev Close | 3.38 |
| Employees | 489 | LT Debt/Eq | 1.26 | Earnings | Oct 29 | SMA200 | -40.62% | Avg Volume | 4.37M | Price | 3.42 |
| IPO Date | Jun 19, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -6.95% -0.13% | Net Debt/EBITDA | -6.69 | Volume | 6,433,665 | Change | 1.18% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | H.C. Wainwright | Buy | $13 |
| Mar-12-26 | Reiterated | Williams Trading | ||
| Feb-20-26 | Reiterated | HC Wainwright & Co. | Buy | $11 |
| Jan-27-26 | Reiterated | Jefferies | Buy | $8.00 |
| Jan-09-26 | Reiterated | BTIG | Buy | |
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight | |
| Jan-08-26 | Reiterated | Raymond James | Outperform | |
| Nov-04-25 | Reiterated | Piper Sandler | Neutral | $10 |
| Aug-05-25 | Reiterated | UBS | $11 → $12 | |
| Aug-05-25 | Reiterated | Wedbush | Outperform | $2.00 |
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 398 | 407 | 334 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 49 | 43 | 51 | — | — | — | — | — | — | |
| Gross Profit | 349 | 365 | 283 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 327 | 337 | 259 | — | — | — | — | — | — | |
| Research and Development | 60 | 68 | 52 | — | — | — | — | — | — | |
| Other Operating Expense | 1 | 1 | 0 | — | — | — | — | — | — | |
| Operating Income | -37 | -41 | -28 | — | — | — | — | — | — | |
| Interest Expense | 27 | 28 | 20 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 9 | 9 | — | — | — | — | — | — | |
| Net Income Before Taxes | -55 | -61 | -39 | — | — | — | — | — | — | |
| Income Taxes | 1 | 1 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -56 | -62 | -39 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -56 | -62 | -39 | — | — | — | — | — | — | |
| Net Income | -56 | -62 | -39 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.23 | -0.26 | -0.17 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.23 | -0.26 | -0.17 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.23 | -0.26 | -0.17 | — | — | — | — | — | — | |
| EBITDA | -26 | -29 | -17 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.08 | 3.45 | 3.57 | — | — | — | — | — | — | |
| Gross Margin | 87.69 | 89.68 | 84.73 | — | — | — | — | — | — | |
| Operating Margin | -9.30 | -10.07 | -8.38 | — | — | — | — | — | — | |
| Net Margin | -14.07 | -15.23 | -11.68 | — | — | — | — | — | — | |
| Shares Outstanding | 242 | 241 | 235 | — | — | — | — | — | — | |
| Market Capitalization | 828 | 1,405 | 1,191 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Reilly Joseph James | See Remarks | Aug 21 '26 | Sale | 3.86 | 3,982 | 15,358 | 145,854 | Aug 25 |
| Hohenleitner Susan | Chief Financial Officer | Aug 21 '26 | Sale | 3.86 | 1,558 | 6,009 | 227,520 | Aug 25 |
| Bishop John E | See Remarks | Aug 21 '26 | Sale | 3.86 | 19,750 | 76,174 | 317,095 | Aug 25 |
| Brady James Parker | Chief Human Resources Officer | Aug 21 '26 | Sale | 3.86 | 15,136 | 58,378 | 245,930 | Aug 25 |
| Foster Eric Duane | Chief Commercial Officer | Aug 21 '26 | Sale | 3.86 | 8,562 | 33,023 | 409,410 | Aug 25 |
| Kelliher Mike | Chief Business Officer | Aug 21 '26 | Sale | 3.86 | 7,758 | 29,922 | 349,660 | Aug 25 |
| Williams Laura A | Chief Patient Officer | Aug 21 '26 | Sale | 3.86 | 10,739 | 41,419 | 367,456 | Aug 25 |
| RAAB MICHAEL | President & CEO | Aug 21 '26 | Sale | 3.86 | 58,574 | 225,914 | 1,619,792 | Aug 25 |
| RAAB MICHAEL | President & CEO | Jul 15 '26 | Option Exercise | 0.99 | 20,834 | 20,626 | 1,720,034 | Jul 17 |
| RAAB MICHAEL | President & CEO | Jul 15 '26 | Sale | 5.06 | 41,668 | 210,923 | 1,678,366 | Jul 17 |
| Williams Laura A | Chief Patient Officer | Jun 18 '26 | Option Exercise | 0.99 | 31,000 | 30,690 | 460,093 | Jun 22 |
| Williams Laura A | Chief Patient Officer | Jun 18 '26 | Sale | 5.99 | 81,898 | 490,487 | 378,195 | Jun 22 |
| RAAB MICHAEL | President & CEO | Jun 15 '26 | Option Exercise | 0.99 | 20,833 | 20,625 | 1,740,866 | Jun 17 |
| RAAB MICHAEL | President & CEO | Jun 15 '26 | Sale | 5.67 | 41,666 | 236,346 | 1,699,200 | Jun 17 |
| Reilly Joseph James | See Remarks | May 21 '26 | Sale | 6.27 | 3,719 | 23,309 | 149,107 | May 22 |